# **INCIDENCE OF NEUTROPENIA AND EFFECTIVENESS OF** PALBOCICLIB IN CLINICAL PRACTICE IN METASTATIC BREAST **CANCER AFTER 4 YEARS OF USE**

JM Vinuesa-Hernando<sup>1</sup>, M Zurera Berjaga<sup>2</sup>, R Gracia Piquer<sup>1</sup>, R Fresquet Molina<sup>1</sup>, P Gómez Rivas<sup>1</sup>, <u>M</u> <u>Gimeno<sup>1</sup></u>, I Varela Martínez<sup>1</sup>, MA Alcácera López<sup>1</sup>

Pharmacy Service<sup>1</sup>. Medical Oncology<sup>2</sup>. Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain

# BACKGROUND

The inhibitor of cyclin-dependent kinases 4 and 6 palbociclib was a major advance in the treatment of metastatic breast cancer.

# **MATERIAL AND METHODS**

Retrospective study of patients with metastatic or Demographic variables were collected: start and end date locally advanced breast cancer treated with the drug, concomitant hormonal treatment and of





Hospital Clínico Universitario "Lozano Blesa"

# **PURPOSE**

To describe the effectiveness and incidence of neutropenia of palbociclib in clinical practice.

palbociclib on any line in a tertiary hospital between

**Period**: July 2016 and August 2020.


### treatment with denosumab.

• The presence of neutropenia was assessed before the start, on day 15 of the first cycle and with each reduction.

# RESULTS

58 patients were included with a median palbociclib starting age of 59.0 years (33-87); the median cycle was 9 (2-34).

**Concomitant Hormonal Treatment** 



The average neutrophil count was reduced by 52.9% from the beginning to the middle of the first cycle.

	Ν	%	Dose	125 mg	100 mg	75 mg
Started at 125 mg	58	100,0%	Date	C1D15	C1D1	C1D1
			No neutropenia	31,0%	7,7%	8,4%
1 <sup>st</sup> reduction to 100 mg	26	44,8%	Grade 1	20,7%	0,0%	8,3%
			Grade 2	24,2%	15,4%	25,0%
2 <sup>n</sup> d reduction to 75 mg	12	20,6%	Grade 3	22,4%	61,5%	58,3%
			Grade 4	1.7%	15.4%	0.0%

Patients with dose reduction were not more likely to progress (p=0.196).

## CONCLUSION

- Haematological toxicity in the form of neutropenia was frequent, from the first cycle and maintained despite successive dose reductions, being necessary these reductions in almost half of the patients. However, these dose reductions were not associated with an increased risk of progression.
- Bone metastasis is very common in metastatic or locally advanced breast cancer.
- Since the authorisation for first-line use (PALOMA-2) it has become a standard of treatment for metastatic or locally advanced.





#### **25th Anniversary EAHP CONGRESS** Contact: <u>jmvinuesa@salud.aragon.es</u>

